reports
- Jonathan Moreland
Savara Inc: 1 director
A director at Savara Inc bought 48,225 shares at 2.044USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Jonathan Moreland
CTBI COMMUNITY TRUST BANCORP INC.
BUSE FIRST BUSEY CORPORATION
VFF VILLAGE FARMS INTERNATIONAL IN
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
CIA CITIZENS INC. CL A
GBLI GLOBAL INDEMNITY PLC
SVRA SAVARA
BRT BRT APARTMENTS
TDW TIDEWATER INC
AMPY AMPLIFY ENERGY
ADV ADVANTAGE SOLUTIONS INC (A)
SMMT SUMMIT THERAPEUTICS INC
BHRB BURKE & HERBERT BANK & TR/VA
DPG DUFF & PHELPS GLOBAL UTIL INCOME FD
GENK GEN RESTAURANT GROUP INC
NKGN NKGEN BIOTECH INC
SLS SELLAS LIFE SCIENCES GROUP INC
Snap Inc: 3 directors
Three Directors at Snap Inc sold after exercising options/sold 243,139 shares at between 8.542USD and 8.595USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compa...
- Dan Salmon
- Dan Salmon
US Internet: What we know (and don’t know) about China/de minimis adve...
On Monday, we analyzed GOOGL and META’s potential exposure to China-based advertisers HERE, and discussed META’s exposure more HERE. Last night, SNAP cited weakness from advertisers impacted by changes to the de mimimus exemption as one example of the macro uncertainty that led it to pull 2Q25 guidance (see HERE for full takeaways). Led by Temu and Shein, there is likely high overlap between China-based retailers and those impacted by de minimis exemption changes.
- Dan Salmon
- Jonathan Moreland
XPL SOLITARIO ZINC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TTSH TILE SHOP HOLDINGS INC.
STAA STAAR SURGICAL CO.
SIG SIGNET JEWELERS LIMITED
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
RGP RESOURCES CONNECTION INC.
PBPB POTBELLY CORP.
PBF PBF ENERGY INC. CLASS A
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
CRM SALESFORCE.COM INC.
CMC COMMERCIAL METALS COMPANY
CDXS CODEXIS
APA.. APA CORP.
AB ALLIANCEBERNSTEIN HOLDING L.P.
FLWS 1-800-FLOWERS.COM CL A
GWRS GLOBAL WATER RESOURCES
JELD JELD-WEN HOLDING INC.
SVRA SAVARA
WGO WINNEBAGO INDUSTRIES INC.
PNBK PATRIOT NATIONAL BANCORP
FF FIRST MINING GOLD
DOMO DOMO INCORPORATED
FUND ROYCE FOCUS TRUST
FGBI INC.
VEL FIRST GUARANTY BANCSHARES
ZYME VELOCITY COMPOSITES
RZLT ZYMEWORKS INC.
WOOF REZOLUTE
UAN INC.
VSCO PETCO HEALTH AND WELLNESS
BTMD CVR PARTNERS LP
EWTX VICTORIA'S SECRET & CO
TEAF HAYMAKER ACQUISITION CORP III
JMSB EDGEWISE THERAPEUTICS INC
ERNA ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
GTE JOHN MARSHALL BANCORP INC
SSII ETERNA THERAPEUTICS INC.
CATX GRAN TIERRA ENERGY INC.
ADVM SS INNOVATIONS INTERNATIONAL INC
SUNS PERSPECTIVE THERAPEUTICS
BNTC INC.
FG ADVERUM BIOTECHNOLOGIES INC.
ALMU SUNRISE REALTY TRUST
FTLF BENITEC BIOPHARMA INC
ECF F AND G ANNUITIES AND LIFE
INC.
AELUMA
INC.
FITLIFE BRANDS INC.
ELLSWORTH FUND LTD
- Jonathan Moreland
OPK OPKO HEALTH INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
SVRA SAVARA
PNBK PATRIOT NATIONAL BANCORP
FUND ROYCE FOCUS TRUST
WOOF INC.
UAN PETCO HEALTH AND WELLNESS
GAM CVR PARTNERS LP
CATX GENERAL DE ALQUILER DE MAQUINARIA
SUNS PERSPECTIVE THERAPEUTICS
AFCG INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramo...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)” at the meeting. ATS 2025 Posters Poster Title: Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients with A...
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot T...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample. The DBS test demonstrates a high correlation between GM-CSF autoantibody levels in dried serum and traditional serum samples, ensuring reliable res...
Savara Announces Participation in the Leerink Global Healthcare Confer...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at and will be archived for 90 days. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our ...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 97,500 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 82,500 shares of the Company’s common stock. These equity a...
- Dan Salmon
Snap Inc. (SNAP, Buy, $16 target) 4Q24 Model Update (Buy, target lower...
Our target declines to $16 from $17 owing to lower estimates, partially offset by a higher valuation owing to growing long-term revenue potential after SNAP’s advertiser base doubled in 2024, while Snapchat+ continues to layer in a more predictable subscription revenue stream.
- Dan Salmon
Snap Inc. (SNAP, Buy, $17 target) Two Very Important Things Doubled in...
What's New: In this first take following tonight's results, we focus on: 1. Upside potential grows as advertiser count and Snapchat+ subs both double in 2024 2. DR/Brand trends right in-line with expectations, helped a little by TikTok, and new ad load 3. Very careful rollout of simplified Snapchat progressing, likely takes all of 2025 to complete
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim In...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, resulting in improved lung function, decreased disease burden, restored patient functionality, and reduction of clinical symptoms, and may enable resumption of daily life activities. This case series retrospectively evaluated five aPAP pati...
Savara Announces Participation in Upcoming Healthcare Investor Confere...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each. Guggenheim SMID Cap Biotech Conference, February 5-6, 2025 Fireside Chat: February 5th, 10:00am ET/7:00am PT Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Fireside Chat: February 11th, 8:00am ET/5:00am PT The live webcasts and subsequent replays will be av...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 100,000 shares of the Company’s common stock. These equity...
Savara Initiates Rolling Submission of a Biologics License Application...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with aPAP. As a result, the Company is allowed to submit individual modules of the BLA as they are completed rather th...
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthca...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan C Room The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at and will...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.